Neal Walker - Jun 1, 2021 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
President and CEO, Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Jun 1, 2021
Transactions value $
-$719,735
Form type
4
Date filed
6/2/2021, 09:41 PM
Next filing
Jun 10, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +73K +6.12% 1.27M Jun 1, 2021 Direct F1
transaction ACRS Common Stock Sale -$597K -27.7K -2.19% $21.51 1.24M Jun 2, 2021 Direct F2, F3
transaction ACRS Common Stock Sale -$123K -5.52K -0.45% $22.30 1.23M Jun 2, 2021 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -73K -100% $0.00* 0 Jun 1, 2021 Common Stock 73K Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2 Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections.
F3 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.005 to $21.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.01 to $22.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020.